Head-to-head evidence
mesalamine (Apriso) vs Mesalamine (Lialda)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline
mesalamine (Apriso)
Marketed by Bausch Health
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Mesalamine (Lialda)
Marketed by Takeda Pharmaceutical Company
NCT00151892 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 829 participants and an objective endoscopic primary endpoint. Lialda was non-inferior to Asacol for six-month endoscopic remission: 83.7% versus 81.5%, with the 95% confidence interval for the difference (-4% to 8%) remaining within the prespecified -10% margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mesalamine (Apriso)'s landscape · Mesalamine (Lialda)'s landscape